Lifeward Ltd. has successfully completed its acquisition of Oratech Pharma, a wholly-owned subsidiary of Oramed Pharmaceuticals, as per the Share Purchase Agreement signed earlier this year. This strategic move is expected to enhance Lifeward's operational capabilities and market presence in the medical technology sector. The acquisition involved the issuance of approximately 2.26 million ordinary shares and warrants, alongside a commitment to share revenue from Lifeward's ReWalk Personal Exoskeleton products. In conjunction with this acquisition, Lifeward has expanded its Board of Directors from five to eight members, appointing three new directors to strengthen governance and oversight. The company expressed gratitude to departing directors Dr. John William Poduska and Randel Richner for their contributions. This expansion and acquisition are anticipated to positively impact Lifeward's growth trajectory and shareholder value.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.